Article: GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years.

New study results also demonstrate the longest duration of consistently high antibody levels shown by a cervical cancer vaccine

TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- New data demonstrate that GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date. Over this time, the cervical cancer candidate vaccine showed 100 percent efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 and also provided substantial protection against ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!